Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Net Cash Flow (2016 - 2025)

Neurocrine Biosciences' Net Cash Flow history spans 16 years, with the latest figure at $372.8 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 421.93% year-over-year to $372.8 million; the TTM value through Dec 2025 reached $480.0 million, up 2751.93%, while the annual FY2025 figure was $480.0 million, 2751.93% up from the prior year.
  • Net Cash Flow reached $372.8 million in Q4 2025 per NBIX's latest filing, up from $76.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $372.8 million in Q4 2025 to a low of -$256.6 million in Q2 2024.
  • Average Net Cash Flow over 5 years is $26.6 million, with a median of $39.3 million recorded in 2021.
  • Peak YoY movement for Net Cash Flow: crashed 794.16% in 2022, then skyrocketed 421.93% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at $29.7 million in 2021, then surged by 75.08% to $52.0 million in 2022, then tumbled by 182.5% to -$42.9 million in 2023, then crashed by 169.93% to -$115.8 million in 2024, then surged by 421.93% to $372.8 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Net Cash Flow are $372.8 million (Q4 2025), $76.4 million (Q3 2025), and $69.7 million (Q2 2025).